Risk of Serious Infections During Treatments for Rheumatoid Arthritis
Author Information
Author(s): Salliot C, Dougados M, Gossec L
Primary Institution: René-Descartes University, Medicine Faculty; AP-HP, Cochin Hospital, Rheumatology B Department, Paris, France
Hypothesis
Do biological agents like rituximab, abatacept, and anakinra increase the risk of serious infections in rheumatoid arthritis patients?
Conclusion
The study found no significant increase in the risk of serious infections with rituximab or abatacept, but high doses of anakinra may increase this risk.
Supporting Evidence
- High doses of anakinra (≥100 mg daily) were associated with an increased risk of serious infections.
- Rituximab and abatacept did not show a statistically significant increased risk of serious infections.
- The overall pooled odds ratios for serious infections were not significantly increased for rituximab and abatacept.
Takeaway
This study looked at whether certain medications for arthritis make people more likely to get really sick. It found that two of the medicines are safe, but one might cause problems if taken in high doses.
Methodology
A systematic review and meta-analysis of randomized controlled trials was conducted to compare serious infection rates between biological agents and placebo.
Potential Biases
Potential bias in patient selection and exclusion of patients with comorbidities may influence results.
Limitations
The study only included published data, which may introduce publication bias, and the trials may not represent all patients with rheumatoid arthritis.
Participant Demographics
Approximately 81% of participants were women, with a mean age between 46 and 57 years.
Statistical Information
Confidence Interval
95% CI: 1.31 to 70.91
Statistical Significance
p>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website